Patient-reported outcomes: the missing link to advancing light chain (AL) amyloidosis clinical research

Systemic light chain (AL) amyloidosis often results in multi-organ dysfunction and significant morbidity. Clinical assessments may not capture the full impact of disease and treatment on patients. Patient-reported outcomes (PROs) can help fill this gap. Although evidence suggests that the use of PRO...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Dittrich, Tobias (VerfasserIn) , Weinert, Lina (VerfasserIn) , D'Souza, Anita Christine (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 May 2025
In: Blood reviews
Year: 2025, Jahrgang: 74, Pages: 1-8
ISSN:1532-1681
DOI:10.1016/j.blre.2025.101303
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.blre.2025.101303
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0268960X25000487
Volltext
Verfasserangaben:Tobias Dittrich, Lina Weinert, Anita D'Souza
Beschreibung
Zusammenfassung:Systemic light chain (AL) amyloidosis often results in multi-organ dysfunction and significant morbidity. Clinical assessments may not capture the full impact of disease and treatment on patients. Patient-reported outcomes (PROs) can help fill this gap. Although evidence suggests that the use of PROs provides additional predictive value beyond established cardiac staging systems, their integration into standard AL amyloidosis management remains limited. Our review examines the prognostic and therapeutic value of PROs and their current use as endpoints in clinical trials. We also discuss practical considerations, including instrument selection and administration, data interpretation, and reporting. Finally, we present a roadmap for integrating PROs into routine AL amyloidosis management, focusing on the selection of appropriate ePRO platforms and implementation strategies. We advocate a framework for data sharing and a coordinated research agenda. By addressing evidence gaps and prioritizing the patient perspective, PROs have the potential to advance AL amyloidosis care and research.
Beschreibung:Gesehen am 03.03.2026
Beschreibung:Online Resource
ISSN:1532-1681
DOI:10.1016/j.blre.2025.101303